LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

SCYNEXIS Inc

Uždarymo kaina

0.69 -4.17

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.69

Max

0.73

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-958K

-5.4M

Pardavimai

-720K

257K

Pelnas, tenkantis vienai akcijai

-0.11

Pelno marža

-2,097.665

Darbuotojai

28

EBITDA

-1.5M

-5.2M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+440.54% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-9.1M

29M

Ankstesnė atidarymo kaina

4.86

Ankstesnė uždarymo kaina

0.69

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

SCYNEXIS Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-26 23:49; UTC

Uždarbis

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

2025-06-26 22:19; UTC

Įsigijimai, susijungimai, perėmimai

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

2025-06-26 21:30; UTC

Uždarbis

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

2025-06-26 21:07; UTC

Uždarbis

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

2025-06-26 23:49; UTC

Rinkos pokalbiai

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

2025-06-26 23:39; UTC

Rinkos pokalbiai

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

2025-06-26 23:34; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

2025-06-26 23:33; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

2025-06-26 23:32; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers Will No Longer Receive Earnings From BWP Management

2025-06-26 23:32; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

2025-06-26 23:31; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

2025-06-26 23:31; UTC

Įsigijimai, susijungimai, perėmimai

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

2025-06-26 23:30; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

2025-06-26 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

2025-06-26 23:19; UTC

Įsigijimai, susijungimai, perėmimai

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

2025-06-26 22:06; UTC

Uždarbis

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

2025-06-26 21:15; UTC

Uždarbis

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

2025-06-26 21:07; UTC

Įsigijimai, susijungimai, perėmimai

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

2025-06-26 21:07; UTC

Įsigijimai, susijungimai, perėmimai

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

2025-06-26 21:07; UTC

Įsigijimai, susijungimai, perėmimai

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

2025-06-26 21:07; UTC

Uždarbis

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

2025-06-26 21:06; UTC

Įsigijimai, susijungimai, perėmimai

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

2025-06-26 21:06; UTC

Įsigijimai, susijungimai, perėmimai

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

2025-06-26 21:06; UTC

Rinkos pokalbiai

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

2025-06-26 21:05; UTC

Įsigijimai, susijungimai, perėmimai

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

2025-06-26 21:05; UTC

Įsigijimai, susijungimai, perėmimai

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

2025-06-26 20:52; UTC

Uždarbis

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

2025-06-26 20:51; UTC

Uždarbis

Correct: Nike 4Q Net $211M, Not $200M >NKE

2025-06-26 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-06-26 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

SCYNEXIS Inc Prognozė

Kainos tikslas

By TipRanks

440.54% į viršų

12 mėnesių prognozė

Vidutinis 4 USD  440.54%

Aukščiausias 4 USD

Žemiausias 4 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines SCYNEXIS Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

0.9307 / 0.9907Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Weak Bearish Evidence

Ilgalaikis periodas

No Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.